hotspot -WSS

hotspot

author：knowledge 2025-09-27 10:00:33 - browse：724

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： The painfully weak evidence on taking collagen to treat arthritis

WSS

Winners, losers from Medicare’s list of drugs subject to price talks

AstraZeneca challenges Medicare drug negotiation program

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Departing Stanford president retracts two papers

Winners, losers from Medicare’s list of drugs subject to price talks

Why more medical students aren't specializing in primary care

focus

hotspot

focus

United colonoscopy coverage change 'may cost lives,' doctors say

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

The cancer drug shortage isn’t new — and neither are the solutions

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

Hollywood unions extend contract negotiations for actors

Diversity in medical illustrations gets boost from Chidiebere Ibe

The cancer drug shortage isn’t new — and neither are the solutions

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Moonlake's readout produced a cash windfall. Risks remain

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

focus

Apellis safety probe of eye disease drug centers on injection needle

Drug firms test therapies to halt Alzheimer’s before symptoms arise

Judge schedules Friday hearing on proposed protective order in Jan. 6 case

2024 GOP presidential candidates spar over abortion in debate

Radiation, mainstay of cancer treatment, begins a fade

How to make AI work for medicine

explore

Wikipedia

hotspot

hotspot